These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 22375612

  • 21. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM.
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [Abstract] [Full Text] [Related]

  • 23. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [Abstract] [Full Text] [Related]

  • 24. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [Abstract] [Full Text] [Related]

  • 25. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, Festa A, Kiljański J, Sapin H, Trautmann M, Schernthaner G.
    Lancet; 2012 Jun 16; 379(9833):2270-8. PubMed ID: 22683137
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G.
    Diabetologia; 2013 Dec 16; 56(12):2582-92. PubMed ID: 24026211
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
    Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM.
    Diabetes Obes Metab; 2010 Jul 16; 12(7):613-22. PubMed ID: 20590736
    [Abstract] [Full Text] [Related]

  • 28. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E, Dotta F, Jia Y, Goodman M.
    Diabetes Obes Metab; 2009 May 16; 11(5):506-15. PubMed ID: 19320662
    [Abstract] [Full Text] [Related]

  • 29. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
    Krobot KJ, Ferrante SA, Davies MJ, Seck T, Meininger GE, Williams-Herman D, Kaufman KD, Goldstein BJ.
    Curr Med Res Opin; 2012 Aug 16; 28(8):1281-7. PubMed ID: 22697277
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov 16; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 31. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
    Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH.
    Diabetes Obes Metab; 2011 Nov 16; 13(11):982-9. PubMed ID: 21615670
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS.
    Diabetologia; 2013 Jul 16; 56(7):1503-11. PubMed ID: 23604551
    [Abstract] [Full Text] [Related]

  • 33. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
    Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK.
    Diabet Med; 2011 Oct 16; 28(10):1176-81. PubMed ID: 21923696
    [Abstract] [Full Text] [Related]

  • 34. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S.
    Diabetes Metab; 2012 Oct 16; 38(4):359-66. PubMed ID: 22809630
    [Abstract] [Full Text] [Related]

  • 35. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF, Mannucci E, Ahrén B.
    Diabetes Obes Metab; 2012 Aug 16; 14(8):762-7. PubMed ID: 22471248
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.
    Clin Ther; 2008 Aug 16; 30(8):1448-60. PubMed ID: 18803987
    [Abstract] [Full Text] [Related]

  • 37. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov 16; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group.
    Diabetes Care; 2006 Dec 16; 29(12):2638-43. PubMed ID: 17130197
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.
    Curr Med Res Opin; 2009 Mar 16; 25(3):569-83. PubMed ID: 19232032
    [Abstract] [Full Text] [Related]

  • 40. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group.
    Diabetes Care; 2014 Mar 16; 37(3):740-50. PubMed ID: 24144654
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.